A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Bernstein analyst Florent Cespedes maintained a Hold rating on Merck KGaA (0O14 – Research Report) today and set a price target of €168.00. The ...

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...

The semiconductor, electronics, and pharmaceutical industries play a vital role in the global high-purity sulfuric acid ...

The global High Content Screening Market , valued at US$1.47 billion in 2024, is forecasted to grow at a robust CAGR of 7.5%, ...

Lübeck – Drägerwerk AG & Co. KGaA increased its order intake in fiscal year 2024 thanks to good demand for medical and safety technology. At around EUR 3,381 million, order intake was around EUR 90 ...

Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

id=8484789 As of 2023, prominent players in analytical standards are Merck KGaA (Germany), Agilent Technologies, Inc. (US), Waters Corporation (US), LGC Limited (UK), PerkinElmer (US), Restek ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that when ...

The VXM01-avelumab combination therapy was generally well-tolerated, with the majority of safety events being mild to moderate in severity. These safety and tolerability data are in-line with ...